<DOC>
	<DOCNO>NCT02492815</DOCNO>
	<brief_summary>Observational study evaluate effectiveness safety ipilimumab , administer European expand access programme ( EAP ) pretreated patient advanced ( unresectable metastatic ) melanoma .</brief_summary>
	<brief_title>PAN-EU Utilization , Effectiveness Safety Ipilimumab Administered EAP Patients With Advanced Melanoma</brief_title>
	<detailed_description>Minimum age : 18 year old ( time inclusion CA184-367- 16 EAP )</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Patients enrol EAPs Patients still alive must provide informed consent require local regulation Deceased patient eligible per local regulation , legal representative must provide informed consent require local regulation There specific exclusion criterion observational study exclusion criterion EAP</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>